EOB that was Gilead and the sale price was 11.4 Billion in 2011 allow for inflation and we could get to 13 Billion , the reason for such valuations is that in Gileads first year of sales they returned $ 13 billion in sales and are still currently doing $5 billion in sales on that compound alone .
Mind you plaxaloid has done $1.5 billion in sales to date too .
Funding Structure, page-25
-
- There are more pages in this discussion • 129 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
